On Monday, August 10, 2026, researchers tracked two new trials that could widen the use of GLP-1 medications beyond their current approvals. One study will look at tirzepatide in Type 1 diabetes, a population that hasn't been part of this drug class's testing so far. Another will pair semaglutide with a new pill for people who have both a liver disease called MASH and obesity. If either trial succeeds, it could open GLP-1 treatment to more people who don't fit today's approved uses.
A Phase 2 trial titled Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes will be the first time this drug is tested in that population, but recruitment has not started. GLP-1 drugs like tirzepatide have mostly been approved and studied for Type 2 diabetes and obesity, so a trial in Type 1 diabetes marks a shift into new territory for the drug class. Because the study hasn't opened yet, there is no enrollment information available, and no results to review. People with Type 1 diabetes who are interested in this trial should watch for updates on when recruitment begins, since that stage hasn't been reached.
The second trial pairs semaglutide with a new pill, CS060380, in people who have both MASH, a form of liver disease, and obesity. This is a Phase 2 study that is currently active, though not recruiting new participants at this time. Testing a combination of two treatments in people who have both conditions together reflects a common pattern in this therapy area, where obesity and liver disease often occur in the same patient. Because enrollment isn't open, people interested in the trial won't be able to join right now, though that status could change as the study proceeds.
For readers following these developments, the key point is that both trials are early stage and won't lead to any near-term change in treatment options. If you have Type 1 diabetes or a diagnosis of MASH with obesity, I would suggest checking the linked trial records periodically for updates on recruitment status, since neither study is currently enrolling. You might also talk with your doctor about whether either trial could be relevant to your care as it moves forward. Following the full records at the links provided will give you the most accurate picture of when, or whether, these studies start recruiting.
Key details
A Phase 2 trial will test tirzepatide in Type 1 diabetes, though it hasn't started.
A new pill paired with semaglutide is being tested in people with MASH and obesity.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-08-10